Perinatal EvidenceCompass
Prepopulated workbenchMED-004

Antidepressants — SSRI

Escitalopram

SSRI antidepressant; mood/anxiety/OCD indications vary

Not a categorical safety rating

This record organizes questions; it does not close them.

The clinical fields and position statements are prepopulated from the public-source corpus. They have not completed individual dual extraction, formal appraisal, exact-label reconciliation, or multidisciplinary sign-off. Do not use this page to justify abrupt discontinuation or reflexive switching.

Inventory identity

What this record represents

Canonical generic name
Escitalopram
Entity type
single-ingredient drug
Active component(s)
Escitalopram
Formulation / route / interval
Oral; formulation varies
Attachment entry
Escitalopram
Separate monograph status
No — cross-reference shared molecule monograph
Identity and cross-reference
Not populated in v0.95
Inventory verification confidence
Moderate — molecule-level source; exact product/jurisdiction pending

Decision taxonomy

Five positions kept separate

These are workbench statements for reviewer execution. They are not independently commissioned, patient-specific recommendations.

  1. 01

    Stable continuation

    Workbench statement

    Do not withhold or discontinue solely because of pregnancy or lactation. For this record, assess indication, prior response, relapse severity, dose/formulation, alternatives, exposure timing, and mapped evidence; individual commissioned adjudication remains pending.

  2. 02

    New initiation in pregnancy

    Workbench statement

    For a new start, prefer an effective option with the strongest diagnosis-specific efficacy and reproductive evidence when clinically suitable. This record has not received an individual, independently verified initiation ranking.

  3. 03

    Switch before conception

    Workbench statement

    Before conception, consider a switch only when expected benefit exceeds relapse, withdrawal, failed-switch, and dual-exposure risks. Build and monitor the plan before pregnancy when feasible; no universal switch direction is assigned here.

  4. 04

    Unplanned exposure

    Workbench statement

    After unplanned exposure, confirm product, route, dose, timing, indication, co-exposures, and symptoms; do not advise abrupt cessation. Use the mapped evidence and current label to decide whether any targeted fetal assessment is indicated.

  5. 05

    Delivery, postpartum & lactation

    Workbench statement

    Create separate delivery, postpartum-dose, neonatal-observation, and lactation plans. Do not infer breastfeeding suitability from pregnancy evidence or routinely taper before delivery without drug-specific support.

Linked evidence

13 mapped claim summaries

Mapping can include class-wide, framework, formulation, regulatory, or evidence-gap claims. A linked claim is not necessarily a drug-specific causal estimate.

A-001Provisional public source

ACOG recommends against withholding or discontinuing a psychiatric medication solely because of pregnancy or lactation.

Public-source certainty descriptor
guideline recommendation; not a formal GRADE rating in this module
Formal appraisal
Not started — full text and independent appraisal pending
Exposure window
preconception through lactation
Comparator
continuation versus withholding/discontinuation
Effect or numbers carried forward

No reliable quantitative estimate.

Limitations

Requires individualized benefit-risk assessment and does not mean every medicine should continue.

Sources, citation controls, and verification state
PMID
37486661
DOI
Pending DOI verification
Exact locator
Pending exact table/figure/page/supplement locator
Access date
2026-07-29
Integrity check
Same-day source surveillance recorded; source-by-source correction/retraction verification remains pending
Internal verification
Source-linked; independent external verification pending
A-002Provisional public source

ACOG considers SSRIs first-line pharmacotherapy for perinatal depression/anxiety and SNRIs reasonable alternatives; prior response should guide selection, with sertraline or escitalopram reasonable for a medication-naive patient.

Public-source certainty descriptor
guideline recommendation; not a formal GRADE rating in this module
Formal appraisal
Not started — full text and independent appraisal pending
Exposure window
pregnancy and postpartum
Comparator
medication choice
Effect or numbers carried forward

No reliable quantitative estimate.

Limitations

Selection still depends on diagnosis, bipolar screening, severity, comorbidity, interactions, past response, and patient preference.

Sources, citation controls, and verification state
PMID
37486661
DOI
Pending DOI verification
Exact locator
Pending exact table/figure/page/supplement locator
Access date
2026-07-29
Integrity check
Same-day source surveillance recorded; source-by-source correction/retraction verification remains pending
Internal verification
Source-linked; independent external verification pending
A-003Provisional public source

In a selected prospective cohort of pregnant patients with recurrent major depression, discontinuation was associated with more relapse than maintenance.

Public-source certainty descriptor
moderate for a high-recurrence population; limited generalizability; not GRADE
Formal appraisal
Not started — full text and independent appraisal pending
Exposure window
pregnancy
Comparator
antidepressant discontinuation versus maintenance
Effect or numbers carried forward

Relapse 68% among 65 discontinuers versus 26% among 82 maintainers.

Limitations

Selected cohort enriched for recurrent illness; nonrandomized treatment decision; not applicable to every patient or drug.

Sources, citation controls, and verification state

Linked sources

PMID
16449615
DOI
Pending DOI verification
Exact locator
Pending exact table/figure/page/supplement locator
Access date
2026-07-29
Integrity check
Same-day source surveillance recorded; source-by-source correction/retraction verification remains pending
Internal verification
Source-linked; independent external verification pending
A-004Provisional public source

A large Medicaid cohort found no substantial SSRI-associated cardiac-malformation increase after restriction to depression and confounding adjustment; specific historical paroxetine and sertraline signals were attenuated.

Public-source certainty descriptor
moderate; large adjusted cohort; not GRADE
Formal appraisal
Not started — full text and independent appraisal pending
Exposure window
first trimester
Comparator
exposed versus unexposed, with depression-restricted analyses
Effect or numbers carried forward

Paroxetine-RVOTO RR 1.07 (95% CI 0.59-1.93); sertraline-VSD RR 1.04 (0.76-1.41); cohort 949,504 pregnancies.

Limitations

Dispensing does not prove ingestion; live-birth and claims limitations; residual confounding and rare defects remain.

Sources, citation controls, and verification state

Linked sources

PMID
24941178
DOI
Pending DOI verification
Exact locator
Pending exact table/figure/page/supplement locator
Access date
2026-07-29
Integrity check
Same-day source surveillance recorded; source-by-source correction/retraction verification remains pending
Internal verification
Source-linked; independent external verification pending
A-005Provisional public source

A Nordic cohort found a small adjusted cardiac association for SSRI/venlafaxine exposure that disappeared in sibling comparison, supporting residual familial or illness confounding.

Public-source certainty descriptor
moderate for absence of a large class effect; not GRADE
Formal appraisal
Not started — full text and independent appraisal pending
Exposure window
early pregnancy
Comparator
exposed versus unexposed and discordant siblings
Effect or numbers carried forward

Adjusted any-cardiac OR 1.15 (95% CI 1.05-1.26); sibling OR 0.92 (0.72-1.17).

Limitations

Sibling analysis has lower power and can introduce other bias; agent-specific precision is limited.

Sources, citation controls, and verification state

Linked sources

PMID
25888213
DOI
Pending DOI verification
Exact locator
Pending exact table/figure/page/supplement locator
Access date
2026-07-29
Integrity check
Same-day source surveillance recorded; source-by-source correction/retraction verification remains pending
Internal verification
Source-linked; independent external verification pending
A-006Provisional public source

Late-pregnancy SSRI exposure may be associated with a small absolute increase in persistent pulmonary hypertension of the newborn; the fully adjusted broad outcome was not statistically significant.

Public-source certainty descriptor
moderate for small absolute risk; residual uncertainty; not GRADE
Formal appraisal
Not started — full text and independent appraisal pending
Exposure window
late pregnancy
Comparator
late SSRI exposure versus no antidepressant exposure
Effect or numbers carried forward

31.5 per 10,000 late-SSRI-exposed versus 20.8 per 10,000 unexposed; adjusted OR 1.10 (0.94-1.29), primary PPHN OR 1.28 (1.01-1.64).

Limitations

Outcome definitions and residual confounding; does not prove causation or identical risk by agent/dose.

Sources, citation controls, and verification state

Linked sources

PMID
26034955
DOI
Pending DOI verification
Exact locator
Pending exact table/figure/page/supplement locator
Access date
2026-07-29
Integrity check
Same-day source surveillance recorded; source-by-source correction/retraction verification remains pending
Internal verification
Source-linked; independent external verification pending
A-007Provisional public source

Late SSRI exposure was associated with delayed neonatal adaptation in a large term-infant cohort, with dose- and agent-dependent findings.

Public-source certainty descriptor
moderate for association; causality and exact phenotype remain uncertain; not GRADE
Formal appraisal
Not started — full text and independent appraisal pending
Exposure window
late pregnancy
Comparator
late SSRI exposure versus no SSRI exposure
Effect or numbers carried forward

11.2% exposed versus 4.4% unexposed; adjusted OR 2.14 (95% CI 1.96-2.32); 280,090 term infants.

Limitations

Composite outcome; term live births; residual confounding by illness, dose selection, and co-exposure.

Sources, citation controls, and verification state

Linked sources

PMID
Not populated in v0.95
DOI
Pending DOI verification
Exact locator
Pending exact table/figure/page/supplement locator
Access date
2026-07-29
Integrity check
Same-day source surveillance recorded; source-by-source correction/retraction verification remains pending
Internal verification
Source-linked; independent external verification pending
A-008Provisional public source

A 2026 single-center target-trial emulation found small Apgar reductions and more meconium with SSRI continuation, but no statistically significant increase in NICU admission, congenital anomalies, or other severe outcomes.

Public-source certainty descriptor
low-to-moderate; hypothesis-strengthening, not definitive; not GRADE
Formal appraisal
Not started — full text and independent appraisal pending
Exposure window
pregnancy continuation
Comparator
continuation versus discontinuation
Effect or numbers carried forward

1-minute Apgar mean difference -0.39 (95% CI -0.60 to -0.18); 5-minute -0.28 (-0.42 to -0.13); meconium OR 1.73 (1.22-2.45); NICU OR 1.23 (0.82-1.83); anomalies OR 1.09 (0.63-1.90); n=1,014.

Limitations

Single center; live births; residual confounding; multiple outcomes; modest sample for rare outcomes.

Sources, citation controls, and verification state

Linked sources

PMID
Not populated in v0.95
DOI
Pending DOI verification
Exact locator
Pending exact table/figure/page/supplement locator
Access date
2026-07-29
Integrity check
Same-day source surveillance recorded; source-by-source correction/retraction verification remains pending
Internal verification
Source-linked; independent external verification pending
A-009Provisional public source

Antidepressant exposure near delivery was associated with a small postpartum-hemorrhage increase in a Medicaid mood/anxiety cohort; delivery awareness is warranted, not routine discontinuation.

Public-source certainty descriptor
moderate for association; residual confounding; not GRADE
Formal appraisal
Not started — full text and independent appraisal pending
Exposure window
near delivery
Comparator
current exposure versus no current antidepressant
Effect or numbers carried forward

PPH 2.8% with no antidepressant, 4.0% with current serotonin reuptake inhibitor, 3.8% with current non-SRI.

Limitations

Claims outcome/exposure; residual severity and obstetric confounding; broad pharmacologic groups.

Sources, citation controls, and verification state

Linked sources

PMID
23965506
DOI
Pending DOI verification
Exact locator
Pending exact table/figure/page/supplement locator
Access date
2026-07-29
Integrity check
Same-day source surveillance recorded; source-by-source correction/retraction verification remains pending
Internal verification
Source-linked; independent external verification pending
A-010Provisional public source

A 2026 systematic review found conventional antidepressant-autism/ADHD associations attenuated or became nonsignificant with illness, familial, genetic, and paternal controls, arguing against a clear causal interpretation.

Public-source certainty descriptor
moderate against a large causal class effect; agent-specific uncertainty; not GRADE
Formal appraisal
Not started — full text and independent appraisal pending
Exposure window
prenatal exposure
Comparator
exposed versus unexposed and negative/familial controls
Effect or numbers carried forward

37 studies; 648,626 exposed and 24,967,806 unexposed children; conventional ADHD RR 1.35 (1.24-1.47) and autism RR 1.69 (1.24-2.30), attenuated in stronger control designs.

Limitations

Heterogeneous studies and outcomes; residual confounding; does not prove zero risk or resolve individual drugs.

Sources, citation controls, and verification state

Linked sources

PMID
42134364
DOI
Pending DOI verification
Exact locator
Pending exact table/figure/page/supplement locator
Access date
2026-07-29
Integrity check
Same-day source surveillance recorded; source-by-source correction/retraction verification remains pending
Internal verification
Source-linked; independent external verification pending
A-067Provisional public source

FDA prescription labeling uses narrative Pregnancy and Lactation Labeling Rule sections rather than the former A/B/C/D/X letter categories.

Public-source certainty descriptor
high for US regulatory framework
Formal appraisal
Not started — full text and independent appraisal pending
Exposure window
pregnancy and lactation
Comparator
not applicable
Effect or numbers carried forward

No reliable quantitative estimate.

Limitations

Exact labeling and revision date remain product-specific; non-US systems differ.

Sources, citation controls, and verification state

Linked sources

PMID
Not populated in v0.95
DOI
Pending DOI verification
Exact locator
Pending exact table/figure/page/supplement locator
Access date
2026-07-29
Integrity check
Same-day source surveillance recorded; source-by-source correction/retraction verification remains pending
Internal verification
Source-linked; independent external verification pending
A-068Provisional public source

Sertraline and paroxetine generally have the lowest SSRI milk transfer and are often preferred for new lactation starts; fluoxetine has higher/longer-lived exposure, but a stable effective regimen should not be switched automatically.

Public-source certainty descriptor
moderate for relative milk-transfer pattern; not GRADE
Formal appraisal
Not started — full text and independent appraisal pending
Exposure window
lactation
Comparator
between-agent milk and infant exposure
Effect or numbers carried forward

No reliable quantitative estimate.

Limitations

Infant age, prematurity, dose, polypharmacy, maternal response, and clinical outcomes matter; low transfer is not zero risk.

Sources, citation controls, and verification state

Linked sources

PMID
Not populated in v0.95
DOI
Pending DOI verification
Exact locator
Pending exact table/figure/page/supplement locator
Access date
2026-07-29
Integrity check
Same-day source surveillance recorded; source-by-source correction/retraction verification remains pending
Internal verification
Source-linked; independent external verification pending
A-070Provisional public source

Routine pre-delivery taper of an effective antidepressant to prevent neonatal adaptation is not recommended; it may precipitate relapse and does not eliminate exposure.

Public-source certainty descriptor
guideline-consistent position; not GRADE
Formal appraisal
Not started — full text and independent appraisal pending
Exposure window
late pregnancy and delivery
Comparator
continuation versus routine taper
Effect or numbers carried forward

No reliable quantitative estimate.

Limitations

Direct randomized taper evidence is limited; individual toxicity or patient preference can still justify a supervised change.

Sources, citation controls, and verification state
PMID
37486661
DOI
Pending DOI verification
Exact locator
Pending exact table/figure/page/supplement locator
Access date
2026-07-29
Integrity check
Same-day source surveillance recorded; source-by-source correction/retraction verification remains pending
Internal verification
Source-linked; independent external verification pending